Welcome to our dedicated page for Oncocyte Corporation news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation stock.
Oncocyte Corporation (OCX) is a pioneering precision diagnostics company dedicated to the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics aimed at facilitating clinical decision-making in the early detection of cancer. The company focuses on molecular tests that address high unmet needs in the diagnosis of lung, breast, and bladder cancers, conditions where current diagnostic standards are often ambiguous, costly, and invasive. Oncocyte's tests are developed based on a proprietary set of biomarkers, designed to differentiate between benign and malignant nodules or masses.
Oncocyte’s flagship products include:
- DetermaIO™: A gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.
- DetermaCNI™: A blood-based monitoring tool for therapeutic efficacy in cancer patients.
- VitaGraft™: A blood-based solid organ transplantation monitoring test.
- GraftAssure™: A research-use-only monitoring test for solid organ transplantation.
The company has made significant strides in expanding its diagnostic capabilities and achieving key regulatory and commercial milestones. In 2023, Oncocyte secured reimbursement for VitaGraft™ Kidney, manufactured the initial lots of GraftAssure RUO, and entered a strategic partnership with Bio-Rad Laboratories to commercialize GraftAssure and develop VitaGraft Kidney IVD. This partnership, along with a successful $15.8 million private placement offering, positions Oncocyte well to meet its critical commercial and regulatory goals.
Oncocyte continues to be supported by strong core investors and aims to provide clarity and confidence to physicians and their patients through its groundbreaking diagnostic tests. For more information, visit www.oncocyte.com.
Oncocyte Corporation (Nasdaq: OCX) announced it will present new data on its DetermaIO™ test at the AACR Annual Meeting 2022 from April 8-13 in New Orleans. The 27-gene expression test helps identify patients with bladder cancer who are likely to respond to immune checkpoint inhibitors (ICIs). This new analysis confirms previous findings linking the IO Score to responses to Genentech’s Tecentriq® therapy. DetermaIO is the first test to evaluate the entire tumor microenvironment, enhancing therapeutic decision-making for patients undergoing immunotherapy.
Oncocyte Corporation (Nasdaq: OCX) reported significant growth in its Q4 2021 results, with revenues up 104% year-over-year to $3.6 million and test volume increasing 54%. The company announced a strategic partnership with Thermo Fisher Scientific for distributed in vitro diagnostic assays. Notably, their DetermaCNI blood monitoring test has shown promising results for detecting cancer recurrence, and they are on track to launch the TheraSure Transplant Monitor in March 2022. Despite growing revenues, operating losses widened to $35.7 million in Q4 2021.
Oncocyte Corporation (Nasdaq: OCX) has announced the release of its financial and operating results for the fourth quarter and year ending December 31, 2021, set for March 10, 2022, post U.S. market close. A conference call will follow at 4:30 PM ET to discuss the results and corporate developments. Oncocyte specializes in precision diagnostics for cancer treatment, offering tests like DetermaRx™ and DetermaIO™ that aid in the diagnosis and monitoring of cancer. The company aims to enhance patient outcomes through its innovative diagnostics solutions.
Oncocyte Corporation (Nasdaq: OCX) announced participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Management will present during a fireside chat on February 15, 2022, at 4:30 PM EST. The conference aims to enhance patient outcomes through personalized diagnostic insights. Notably, Oncocyte offers proprietary tests like DetermaRx™ and DetermaIO™ to assist in cancer diagnosis and treatment. Investors can reach out to BTIG representatives for meeting opportunities, though the presentation won't be webcast.
Oncocyte Corporation (Nasdaq: OCX) announced a collaboration with Thermo Fisher Scientific to develop and co-market in vitro diagnostic (IVD) assays utilizing Thermo Fisher’s Ion Torrent Genexus System. The agreement includes clinical validation of the Oncomine Comprehensive Assay Plus for tumor profiling and development of Oncocyte’s DetermaIO™ test. The IVD assays aim to enhance precision medicine accessibility, potentially benefiting a significant portion of newly diagnosed cancer patients. The partnership leverages Thermo Fisher’s global capabilities to expand IVD availability beyond the U.S.
Oncocyte Corporation (Nasdaq: OCX) announced that its DetermaCNI test has demonstrated higher sensitivity in detecting cancer recurrence compared to standard biomarkers, showcasing 91% sensitivity at diagnosis and 86% sensitivity during treatment, with a low false positive rate of 5%. This blood-based test offers a genome-wide assessment without the need for tissue samples, making it an innovative solution for cancer monitoring, particularly for ovarian cancer patients, addressing significant unmet needs in treatment evaluation.
Oncocyte Corporation (OCX) announced significant advancements for its DetermaIO test at the SABCS 2021, showcasing its ability to predict responses to immunotherapies in triple negative breast cancer (TNBC). The test achieved a 92% concordance with RNA-sequencing data, emphasizing its reliability across different platforms. It is expected to enhance patient outcomes by identifying candidates for immunotherapy, thus addressing a critical unmet need. DetermaIO has previously demonstrated efficacy in other cancers, reinforcing its potential for pan-cancer diagnostic testing globally.
Oncocyte Corporation (Nasdaq: OCX) has successfully completed the second phase of a three-step technology transfer under its Exclusive Sublicense Agreement with Burning Rock Biotech. This milestone includes a $2M payment and allows Burning Rock to commercially launch the DetermaRx™ test for early-stage lung cancer in China, where the potential patient population is significantly larger than in the U.S. The third phase, involving software validation and another $1M payment, is expected by April 30, 2022.
Oncocyte Corporation (Nasdaq: OCX) announced a business update call scheduled for December 14, 2021, focusing on its DetermaIO immunotherapy response prediction test and TheraSure Transplant Monitor test. The management team will provide an update on the pipeline and highlight key milestones for major products anticipated in 2022.
DetermaIO is a gene expression test that predicts responses to immuno-oncology therapies, while TheraSure monitors organ transplant health using a blood test, reducing the need for invasive procedures.
Oncocyte Corporation (Nasdaq: OCX) announced new data on its DetermaIO test, which predicts response to immunotherapy in cancers like lung and triple-negative breast cancer. The test will be presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) on December 8 and 9. The DetermaIO test assesses the entire tumor microenvironment to help identify suitable patients for immunotherapy. Oncocyte aims to improve cancer treatment outcomes through precision diagnostics and will provide further results after the market closes on December 9, 2021.
FAQ
What is the current stock price of Oncocyte Corporation (OCX)?
What is the market cap of Oncocyte Corporation (OCX)?
What does Oncocyte Corporation specialize in?
What types of cancer does Oncocyte's diagnostics target?
What are some of Oncocyte's key products?
How does Oncocyte's DetermaIO™ test work?
What recent achievements has Oncocyte made?
Who are some of Oncocyte's partners?
What is the purpose of Oncocyte's VitaGraft™ test?
What is GraftAssure™ used for?
How does Oncocyte support its operations financially?
Where can I find more information about Oncocyte Corporation?
